Nature Communications (Nov 2022)
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
- Zhaoqing Tang,
- Yan Wang,
- Dan Liu,
- Xuefei Wang,
- Chen Xu,
- Yiyi Yu,
- Yuehong Cui,
- Cheng Tang,
- Qian Li,
- Jing Sun,
- Qian Zhang,
- Yuan Ji,
- Guifen Ma,
- Haojie Li,
- Zhenbin Shen,
- Kuntang Shen,
- Rongrong Zheng,
- Zhiguo Hou,
- Tianshu Liu,
- Jiping Wang,
- Yihong Sun
Affiliations
- Zhaoqing Tang
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Yan Wang
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Dan Liu
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Xuefei Wang
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Chen Xu
- Department of Pathology, Zhongshan Hospital, Fudan University
- Yiyi Yu
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Yuehong Cui
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Cheng Tang
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Qian Li
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Jing Sun
- Department of Radiotherapy, Zhongshan Hospital, Fudan University
- Qian Zhang
- Department of Radiotherapy, Zhongshan Hospital, Fudan University
- Yuan Ji
- Department of Pathology, Zhongshan Hospital, Fudan University
- Guifen Ma
- Department of Radiotherapy, Zhongshan Hospital, Fudan University
- Haojie Li
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Zhenbin Shen
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Kuntang Shen
- Department of General Surgery, Zhongshan Hospital, Fudan University
- Rongrong Zheng
- Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Zhiguo Hou
- Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Tianshu Liu
- Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Jiping Wang
- Division of Surgical Oncology, Brigham and Women’s Hospital, Harvard Medical School
- Yihong Sun
- Department of General Surgery, Zhongshan Hospital, Fudan University
- DOI
- https://doi.org/10.1038/s41467-022-34403-5
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Surgery is an important part of treatment for gastric adenocarcinoma, however, the consensus on perioperative care is less clear. Here, the authors report the results of a phase II clinical trial investigating neoadjuvant camrelizumab with concurrent chemoradiotherapy, followed by surgery for the treatment of advanced gastric adenocarcinoma.
